Minerva Neurosciences
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Minerva Neurosciences sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
Minerva Neurosciences: 4 sponsored US clinical trials, 1 recruiting.
Minerva Neurosciences sponsors 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 3 completed. 2 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Negative Symptoms of Schizophrenia, with 1 trials.
Upper-quartile sponsor footprint
Minerva Neurosciences sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
4 total, page 1 of 1
Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications
NCT07565428
A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Co-Administration of Roluperidone and Olanzapine in Adult Subjects With Moderate to Severe Negative Symptoms of Schizophrenia
NCT06107803
A Study to Evaluate the Efficacy and Safety of MIN-117 in Adult Patients With Major Depressive Disorder
NCT03446846
Study to Evaluate Efficacy and Safety of Roluperidone (MIN-101) in Adult Patients With Negative Symptoms of Schizophrenia
NCT03397134
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
| Phase 3 | 2 |
Therapeutic Areas
What is open in the Minerva Neurosciences pipeline
1 recruiting of 4 indexed (25% open); 3 completed (75%).
Phase mix: 2 late (III/IV) vs 2 early (I/II) (balanced across stages).
Top condition: Negative Symptoms of Schizophrenia (1 trial), 0 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Minerva Neurosciences: open-pipeline peers nationwide
Peers matched on 4 registered trials and 25% open enrollment, not the therapeutic-area sidebar.
Minerva Neurosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 trials (± recruiting share)
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors near 25% open enrollment (± trial volume)
- AB Science · 25% recruiting · 8 trials
- Abbott Point of Care · 25% recruiting · 8 trials
- Accutar Biotechnology · 25% recruiting · 4 trials
- Adrienne G. Waks · 25% recruiting · 4 trials
Related
What to do with this Minerva Neurosciences page
4 registered trials is a research-attention snapshot, not an endorsement of Minerva Neurosciences or any single study.
- 1 of Minerva Neurosciences's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Negative Symptoms of Schizophrenia is the condition Minerva Neurosciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Negative Symptoms of Schizophrenia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Minerva Neurosciences pipeline card: 4 registered trials from official public datasets.Report a data error.